263 related articles for article (PubMed ID: 11713603)
1. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
2. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
5. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
6. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma.
Lundgren C; Auer G; Frankendal B; Moberger B; Nilsson B; Nordström B
Int J Gynecol Cancer; 2002; 12(1):110-8. PubMed ID: 11860545
[TBL] [Abstract][Full Text] [Related]
7. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
8. Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.
Skirnisdottir I; Seidal T; Åkerud H
Int J Gynecol Cancer; 2015 Sep; 25(7):1239-47. PubMed ID: 26035126
[TBL] [Abstract][Full Text] [Related]
9. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
10. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of DNA quantification in early epithelial ovarian carcinoma.
Valverde JJ; Martin M; García-Asenjo JA; Casado A; Vidart JA; Díaz-Rubio E
Obstet Gynecol; 2001 Mar; 97(3):409-16. PubMed ID: 11239647
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y
BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194
[TBL] [Abstract][Full Text] [Related]
13. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
Bar JK; Słomska I; Rabczyńki J; Noga L; Gryboś M
Int J Gynecol Cancer; 2009 Nov; 19(8):1322-8. PubMed ID: 20009884
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
[TBL] [Abstract][Full Text] [Related]
16. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Skírnisdóttir I; Seidal T; Karlsson MG; Sorbe B
Int J Oncol; 2005 Jan; 26(1):177-83. PubMed ID: 15586238
[TBL] [Abstract][Full Text] [Related]
18. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
